Enhanced antifungal activity of voriconazole-loaded nanostructured lipid carriers against Candida albicans with a dimorphic switching model
نویسندگان
چکیده
Candida commonly adheres to implanted medical devices and forms biofilms. Due to the minimal activity of current antifungals against biofilms, new drugs or drug-delivery systems to treat these persistent infections are urgently needed. In the present investigation, voriconazole-loaded nanostructured lipid carriers (Vrc-NLCs) were formulated for enhanced drug-delivery efficiency to C. albicans to increase the antifungal activity of Vrc and to improve the treatment of infectious Candida diseases. Vrc-NLCs were prepared by a hot-melt, high-pressure homogenization method, and size distribution, ζ-potential, morphology, drug-encapsulation efficiency, drug loading, and physical stability were characterized. The antifungal activity of Vrc-NLCs in vitro was tested during planktonic and biofilm growth in C. albicans. The mean particle size of the Vrc-NLCs was 45.62±0.53 nm, and they exhibited spheroid-like morphology, smooth surfaces, and ζ-potential of -0.69±0.03 mV. Encapsulation efficiency and drug loading of Vrc-NLCs were 75.37%±2.65% and 3.77%±0.13%, respectively. Physical stability results revealed that despite the low measured ζ-potential, the dispersion of the Vrc-NLCs was stable during their 3-week storage at 4°C. The minimum inhibitory concentration of Vrc-NLCs was identical to that of Vrc. However, the inhibition rate of Vrc-NLCs at lower concentrations was significantly higher than that of Vrc during planktonic growth in C. albicans in yeast-extract peptone dextrose medium. Surprisingly, Vrc-NLCs treatment reduced cell density in biofilm growth in C. albicans and induced more switches form hyphal cells to yeast cells compared with Vrc treatment. In conclusion, Vrc-NLCs maintain antifungal activity of Vrc and increase antifungal drug-delivery efficiency to C. albicans. Therefore, Vrc-NLCs will greatly contribute to the treatment of infectious diseases caused by C. albicans.
منابع مشابه
The Phenotypic variation of Candida albicans and susceptibility to fluconazole and voriconazole
Candida albicans is the most frequent opportunistic fungal agent in human being. One of its virulence factors is phenotypic switching. In this study, we investigated the susceptibility of different phenotypes of C. albicans, obtained from clinical specimens, to fluconazole (FLZ) and voriconazole (VRZ) with microdilution reference method. In this study, 281 C. albicans of six different phenotype...
متن کاملIn vitro activity of voriconazole against Candida species.
The in vitro activity of voriconazole was compared with that of itraconazole and fluconazole against 181 isolates of Candida albicans, 124 isolates of Candida glabrata, and 20 isolates of Candida krusei obtained from the early 1980s through the mid-1990s. Voriconazole had greater intrinsic activity than fluconazole or itraconazole against all three Candida species. For C. glabrata, C. krusei, a...
متن کاملNanostructured lipid carriers loaded with Melaleuca alternifolia Oil preparation, physicochemical assessment, and evaluation of antimicrobial effects against Staphylococcus epidermidis
Thanks to their outstanding advantages, nanostructured lipid carriers (NLCs) have recognized in various fields these days. One way to discover extra useful products against typical bacteria (e.g., Staphylococcus epidermidis) is NLCs loaded with essential oils. This paper aims to provide NLCs to encapsulate MA oil and characterize and survey the obtained MA...
متن کاملNanostructured lipid system as a strategy to improve the anti-Candida albicans activity of Astronium sp.
The genus Astronium (Anacardiaceae) includes species, such as Astronium fraxinifolium, Astronium graveolens, and Astronium urundeuva, which possess anti-inflammatory, anti-ulcerogenic, healing, and antimicrobial properties. Nanostructured lipid systems are able to potentiate the action of plant extracts, reducing the required dose and side effects and improving antimicrobial activity. This work...
متن کاملVoriconazole: the newest triazole antifungal agent.
BUMC PROCEEDINGS 2003;16:241–248 Fungal infections remain a significant cause of morbidity and mortality despite advances in medicine and the emergence of new antifungal agents (1). Immunocompromised patients are particularly at risk of developing these infections, with Candida and Aspergillus spp. being the mycoses most commonly identified (2). Patients who develop candidemia have a greater ch...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 12 شماره
صفحات -
تاریخ انتشار 2017